Organization
Medica Scientia Innovation Research (MEDSIR)
12 abstracts
Abstract
Second-line endocrine therapy (ET) with or without palbociclib (P) maintenance in patients (pts) with hormone receptor-positive (HR[+])/human epidermal growth factor receptor 2-negative (HER2[-]) advanced breast cancer (ABC): PALMIRA trial.Org: Kent Oncology Centre, Istituto Europeo Oncologico, Hôpital Européen Georges Pompidou, Medica Scientia Innovation Research (MEDSIR), Pangaea Oncology,
Abstract
3-year invasive disease-free survival (iDFS) of the strategy-based, randomized phase II PHERGain trial evaluating chemotherapy (CT) de-escalation in human epidermal growth factor receptor 2-positive (HER2[+]) early breast cancer (EBC).Org: International Breast Cancer Center (IBCC), Pangaea Oncology, Quiron Group, Medica Scientia Innovation Research (MEDSIR), Universidad Europea de Madrid,
Abstract
Early prediction of endocrine responsiveness in ER+/HER2 negative MBC: Pilot study with 18F-fluoroestradiol (18F-FES) CT/PET.Org: EO Ospedali Galliera, University Hospital Munich, International Breast Cancer Center (IBCC), Vall d'Hebron Institute of Oncology, Maggiore della Carità University Hospital,
Abstract
Prevention of sacituzumab govitecan (SG)-related neutropenia and diarrhea in patients (pts) with triple-negative or HR+/HER2- advanced breast cancer (ABC; PRIMED): A phase 2 trial.Org: International Breast Cancer Center (IBCC), Pangaea Oncology, Quiron Group, Medica Scientia Innovation Research (MEDSIR), Oncoclínicas&Co,
Abstract
Ipatasertib (IPA) combined with non-taxane chemotherapy (CT) for patients (pts) with previously treated advanced triple-negative breast cancer (aTNBC): The PATHFINDER phase IIa trial.Org: Medica Scientia Innovation Research (MEDSIR) - Oncoclínicas&Co, International Breast Cancer Center (IBCC), Pangaea Oncology, Quiron Group, Hospital Universitario Ramón y Cajal,
Abstract
Impact of prophylactic laser therapy on mucositis in patients with head and neck cancer (HNC) undergoing radiotherapy in Brazil.Org: Oncoclinicas & Co - Medica Scientia Innovation Research (MEDSIR), Rio De Janeiro, Brazil, Medica Scientia Innovation Research (MEDSIR),
Abstract
A portrait of germline pathogenic variants from a large real-world cohort of Brazilian patients with breast cancer.Org: Oncoclinicas & Co - Medica Scientia Innovation Research (MEDSIR), Rio De Janeiro, Brazil, Medica Scientia Innovation Research (MEDSIR), Pfizer,
Abstract
Interventions of the nurse navigator in the identification and management of toxicities after the start of treatment in patients with cancer using antineoplastic therapy.Org: Oncoclinicas & Co - Medica Scientia Innovation Research (MEDSIR), Rio De Janeiro, Brazil, Medica Scientia Innovation Research (MEDSIR),
Abstract
Can PSMA-PET be a better way to select patients for an intermittent treatment? Results from a prospective cohort.Org: Oncoclinicas & Co - Medica Scientia Innovation Research (MEDSIR), Rio De Janeiro, Brazil, Medica Scientia Innovation Research (MEDSIR), Hospital DF Star,
Abstract
Co-occurrence of germline pathogenic variants in a Brazilian cohort of patients with breast cancer.Org: Oncoclinicas & Co - Medica Scientia Innovation Research (MEDSIR), Rio De Janeiro, Brazil, Medica Scientia Innovation Research (MEDSIR),
Abstract
Advance care planning and predictive factors among Brazilian patients with cancer from an outpatient palliative care program.Org: Oncoclinicas & Co - Medica Scientia Innovation Research (MEDSIR), Rio De Janeiro, Brazil, Medica Scientia Innovation Research (MEDSIR),
Abstract
Phase II study of the efficacy of retifanlimab (Rf) (INCMGA00012) in penile squamous cell carcinoma (PSqCC): ORPHEUS final analysis.Org: Medical Oncology Group, Institut Català d'Oncologia (ICO) L ́Hospitalet and Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy, Hospital Universitario 12 de Octubre (CIBERONC), IRCCS Ospedale San Raffaele,